{"id":46624,"date":"2026-01-22T11:47:45","date_gmt":"2026-01-22T10:47:45","guid":{"rendered":"https:\/\/www.satt.fr\/?p=46624"},"modified":"2026-01-22T11:51:45","modified_gmt":"2026-01-22T10:51:45","slug":"oragen-therapeutics-capital","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/oragen-therapeutics-capital\/","title":{"rendered":"Oragen Therapeutics et SATT Sayens : un partenariat strat\u00e9gique pour r\u00e9volutionner les MICI"},"content":{"rendered":"<h2><strong>Une avanc\u00e9e majeure pour les maladies inflammatoires chroniques de l\u2019intestin (MICI)<\/strong><\/h2>\n<h4>La SATT Sayens annonce la signature d\u2019un <strong>contrat de licence exclusif<\/strong> avec la biotech <strong>Oragen Therapeutics<\/strong>, ainsi qu\u2019une <strong>prise de participation au capital<\/strong>.<\/h4>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #c90f4c;\"><strong>Objectif : r\u00e9volutionner le traitement des MICI gr\u00e2ce aux ARN th\u00e9rapeutiques par voie orale.<\/strong><\/span><\/p>\n<p>Cette innovation, d\u00e9velopp\u00e9e \u00e0 Besan\u00e7on au sein de l\u2019Unit\u00e9 RIGHT en collaboration avec le CHU, ouvre une nouvelle voie th\u00e9rapeutique pour la maladie de Crohn et la rectocolite h\u00e9morragique, avec un impact potentiel majeur sur un march\u00e9 mondial de <strong>plus de 30 milliards de dollars par an<\/strong>.<\/p>\n<p><span style=\"color: #c90f4c;\"><strong>Pourquoi c\u2019est un tournant ?<\/strong><\/span><\/p>\n<ul>\n<li>administration orale d\u2019ARN th\u00e9rapeutiques<\/li>\n<li>ciblage des tissus inflamm\u00e9s<\/li>\n<li>am\u00e9lioration de l\u2019efficacit\u00e9 et de la tol\u00e9rance<\/li>\n<li>alternative aux traitements injectables<\/li>\n<\/ul>\n<p><span style=\"color: #c90f4c;\"><strong>Un partenariat strat\u00e9gique pour renforcer l\u2019\u00e9cosyst\u00e8me biotech fran\u00e7ais<\/strong><\/span><\/p>\n<p>Oragen Therapeutics, incub\u00e9e au sein de DECA-BFC, s\u2019appuie sur une \u00e9quipe scientifique de haut niveau et vise \u00e0 devenir un leader mondial dans les ARN oraux.<\/p>\n<p><strong><a href=\"https:\/\/www.sayens.fr\/actualites\/reussite\/participation-capital-oragen-therapeutics\/\" target=\"_blank\" rel=\"noopener\">Pour en savoir +<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Une avanc\u00e9e majeure pour les maladies inflammatoires chroniques de l\u2019intestin (MICI) La SATT Sayens annonce la signature d\u2019un contrat de licence exclusif avec la biotech Oragen Therapeutics, ainsi qu\u2019une prise de participation au capital. &nbsp; Objectif : r\u00e9volutionner le traitement des MICI gr\u00e2ce aux ARN th\u00e9rapeutiques par voie orale. Cette innovation, d\u00e9velopp\u00e9e \u00e0 Besan\u00e7on au [&hellip;]<\/p>\n","protected":false},"author":34,"featured_media":46625,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[536],"tags":[],"class_list":["post-46624","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oragen Therapeutics et SATT Sayens : un partenariat strat\u00e9gique pour r\u00e9volutionner les MICI - R\u00e9seau SATT<\/title>\n<meta name=\"description\" content=\"La SATT Sayens annonce la signature d\u2019un contrat de licence exclusive avec la biotech Oragen Therapeutics, ainsi qu\u2019une prise de participation au capital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/oragen-therapeutics-capital\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anthony Petit\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/oragen-therapeutics-capital\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/oragen-therapeutics-capital\\\/\"},\"author\":{\"name\":\"Anthony Petit\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#\\\/schema\\\/person\\\/6a5a84617bc785ef388bd1eb3a23c650\"},\"headline\":\"Oragen Therapeutics et SATT Sayens : un partenariat strat\u00e9gique pour r\u00e9volutionner les MICI\",\"datePublished\":\"2026-01-22T10:47:45+00:00\",\"dateModified\":\"2026-01-22T10:51:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/oragen-therapeutics-capital\\\/\"},\"wordCount\":192,\"image\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/oragen-therapeutics-capital\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.satt.fr\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/IMAGE-ACTU-ORAGEN.jpg\",\"articleSection\":[\"Actualit\u00e9\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/oragen-therapeutics-capital\\\/\",\"url\":\"https:\\\/\\\/www.satt.fr\\\/oragen-therapeutics-capital\\\/\",\"name\":\"Oragen Therapeutics et SATT Sayens : un partenariat strat\u00e9gique pour r\u00e9volutionner les MICI - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/oragen-therapeutics-capital\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/oragen-therapeutics-capital\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.satt.fr\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/IMAGE-ACTU-ORAGEN.jpg\",\"datePublished\":\"2026-01-22T10:47:45+00:00\",\"dateModified\":\"2026-01-22T10:51:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#\\\/schema\\\/person\\\/6a5a84617bc785ef388bd1eb3a23c650\"},\"description\":\"La SATT Sayens annonce la signature d\u2019un contrat de licence exclusive avec la biotech Oragen Therapeutics, ainsi qu\u2019une prise de participation au capital.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/oragen-therapeutics-capital\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.satt.fr\\\/oragen-therapeutics-capital\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/oragen-therapeutics-capital\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.satt.fr\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/IMAGE-ACTU-ORAGEN.jpg\",\"contentUrl\":\"https:\\\/\\\/www.satt.fr\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/IMAGE-ACTU-ORAGEN.jpg\",\"width\":1500,\"height\":971},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/oragen-therapeutics-capital\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oragen Therapeutics et SATT Sayens : un partenariat strat\u00e9gique pour r\u00e9volutionner les MICI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#\\\/schema\\\/person\\\/6a5a84617bc785ef388bd1eb3a23c650\",\"name\":\"Anthony Petit\",\"url\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/author\\\/anthony-petitsayens-fr\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oragen Therapeutics et SATT Sayens : un partenariat strat\u00e9gique pour r\u00e9volutionner les MICI - R\u00e9seau SATT","description":"La SATT Sayens annonce la signature d\u2019un contrat de licence exclusive avec la biotech Oragen Therapeutics, ainsi qu\u2019une prise de participation au capital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/oragen-therapeutics-capital\/","twitter_misc":{"Written by":"Anthony Petit","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/oragen-therapeutics-capital\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/oragen-therapeutics-capital\/"},"author":{"name":"Anthony Petit","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6a5a84617bc785ef388bd1eb3a23c650"},"headline":"Oragen Therapeutics et SATT Sayens : un partenariat strat\u00e9gique pour r\u00e9volutionner les MICI","datePublished":"2026-01-22T10:47:45+00:00","dateModified":"2026-01-22T10:51:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/oragen-therapeutics-capital\/"},"wordCount":192,"image":{"@id":"https:\/\/www.satt.fr\/oragen-therapeutics-capital\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2026\/01\/IMAGE-ACTU-ORAGEN.jpg","articleSection":["Actualit\u00e9"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/oragen-therapeutics-capital\/","url":"https:\/\/www.satt.fr\/oragen-therapeutics-capital\/","name":"Oragen Therapeutics et SATT Sayens : un partenariat strat\u00e9gique pour r\u00e9volutionner les MICI - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/oragen-therapeutics-capital\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/oragen-therapeutics-capital\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2026\/01\/IMAGE-ACTU-ORAGEN.jpg","datePublished":"2026-01-22T10:47:45+00:00","dateModified":"2026-01-22T10:51:45+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6a5a84617bc785ef388bd1eb3a23c650"},"description":"La SATT Sayens annonce la signature d\u2019un contrat de licence exclusive avec la biotech Oragen Therapeutics, ainsi qu\u2019une prise de participation au capital.","breadcrumb":{"@id":"https:\/\/www.satt.fr\/oragen-therapeutics-capital\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/oragen-therapeutics-capital\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/oragen-therapeutics-capital\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2026\/01\/IMAGE-ACTU-ORAGEN.jpg","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2026\/01\/IMAGE-ACTU-ORAGEN.jpg","width":1500,"height":971},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/oragen-therapeutics-capital\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Oragen Therapeutics et SATT Sayens : un partenariat strat\u00e9gique pour r\u00e9volutionner les MICI"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6a5a84617bc785ef388bd1eb3a23c650","name":"Anthony Petit","url":"https:\/\/www.satt.fr\/en\/author\/anthony-petitsayens-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/46624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=46624"}],"version-history":[{"count":6,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/46624\/revisions"}],"predecessor-version":[{"id":46632,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/46624\/revisions\/46632"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/46625"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=46624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=46624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=46624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}